Edit ModuleShow Tags

Health Beat

The Centers for Medicare and Medicaid Services have reported that Medicare Part D drug plans will get more expensive in 2009, up roughly $3 per month from ’08. Payments will now be $28 a month for beneficiaries – a 12 percent increase from ’08.
The fee will not cover all program costs, however. Medicare will still need to subsidize drug coverage with an estimated $36 billion, as the program’s basic plans only cover about 25 percent of costs. The change, Medicare officials say, is less than estimates indicated, due to lesser member enrollment, lower-than-expected drug prices and negotiable insuring agents; critics, however, assert that the changes won’t be enough to match natural cost-of-living increases.
Also in 2009, the Medicare coverage gap will widen. This means in ’09, patients will pay for 100 percent of prescriptions once an initial $2,700 is used up; Medicare will pay bills again once the patient incurs $4,350 or more in charges. This means patients using over $4,350 in drug benefits will wind up spending $1,650 on gap payments for ’09. Patients in ’08 paid less – $1,540. nCongratulations to Dr. Margaret Tennyson, Professor of Nursing at Louisiana State University Health Sciences Center New Orleans School of Nursing, recently appointed by Governor Bobby Jindal to a two-year term on the Louisiana Advisory Committee on Midwifery. This committee establishes and manages midwifery standards. Tennyson has been a Certified Nurse Midwife since 1997.
nChu Chen, Ph.D., Associate Professor of Neuroscience at LSU Health Sciences Center in New Orleans, published a piece August 15 in the Journal of Biological Chemistry positing endogenous (“from within”) cannabinoids can protect the brain from diseases like Alzheimer’s and Parkinson’s.  
Chen found that 2-Arachidonoylglycerol (2-AG), a cannabinoid produced naturally by the body (an endocannabinoid), seemed to lessen the inflammation encouraged by one enzyme, Cyclooxygenase-2 (COX-2).
“Our findings provide a basis for opening up new therapeutic approaches to protect neurons from inflammation and toxicity-induced neurodegeneration,” says Chen, quoted from an LSUHSC press release. Where classic COX-2 inhibitors led to cardiovascular complications in some patients, “the use of endogenous cannabinoid 2-AG may avoid such side effects,” Chen says. (CB1 and CB2 receptors are largely non-present in the medulla oblongata, the brain’s control center for respiratory and cardiovascular function.)
The full text of Chen’s study, “Endocannabinoid 2-Arachidonoylglycerol Protects Neurons by Limiting COX-2 Elevation,” is online at www.jbc.org.

You Might Also Like

Add your comment:
Edit ModuleShow Tags

Latest Posts

One-Two Punch

Skincare that plumps, covers, protects, nourishes and soothes

The Monuments: Wisdom From Andrew Young

Goodbye, Summer

The 2017 Summer in Pictures

La La Fest gives place to budding artists

New arts festival focuses on live crafts

Photographic Memory

Expert advice on getting wedding photos that last a lifetime
Edit ModuleShow Tags
Edit ModuleShow Tags
Edit ModuleShow Tags